359 related articles for article (PubMed ID: 23409121)
1. HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
van der Groep P; van Diest PJ; Smolders YH; Ausems MG; van der Luijt RB; Menko FH; Bart J; de Vries EG; van der Wall E
PLoS One; 2013; 8(2):e56055. PubMed ID: 23409121
[TBL] [Abstract][Full Text] [Related]
2. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
3. High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer.
van der Groep P; Bouter A; Menko FH; van der Wall E; van Diest PJ
Breast Cancer Res Treat; 2008 Oct; 111(3):475-80. PubMed ID: 18030615
[TBL] [Abstract][Full Text] [Related]
4. Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.
Vermeulen MA; van Deurzen CH; Schroder CP; Martens JW; van Diest PJ
J Clin Pathol; 2020 Apr; 73(4):204-208. PubMed ID: 31653758
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
6. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
7. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ in BRCA mutation carriers.
Hwang ES; McLennan JL; Moore DH; Crawford BB; Esserman LJ; Ziegler JL
J Clin Oncol; 2007 Feb; 25(6):642-7. PubMed ID: 17210933
[TBL] [Abstract][Full Text] [Related]
9. Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among
Faermann R; Friedman E; Kaidar-Person O; Weidenfeld J; Brodsky M; Shalmon A; Halshtok Neiman O; Gotlieb M; Yagil Y; Samoocha D; Madorsky Feldman D; Sklair-Levy M
Breast J; 2022; 2022():4317693. PubMed ID: 36349178
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.
Chen CL; Chu JS; Su WC; Huang SC; Lee WY
Virchows Arch; 2010 Jul; 457(1):53-61. PubMed ID: 20526721
[TBL] [Abstract][Full Text] [Related]
11. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
Bayraktar S; Elsayegh N; Gutierrez Barrera AM; Lin H; Kuerer H; Tasbas T; Muse KI; Ready K; Litton J; Meric-Bernstam F; Hortobagyi GN; Albarracin CT; Arun B
Cancer; 2012 Mar; 118(6):1515-22. PubMed ID: 22009639
[TBL] [Abstract][Full Text] [Related]
14. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
[TBL] [Abstract][Full Text] [Related]
15. DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
Yang RL; Mick R; Lee K; Graves HL; Nathanson KL; Domchek SM; Kelz RR; Zhang PJ; Czerniecki BJ
J Transl Med; 2015 Oct; 13():335. PubMed ID: 26496879
[TBL] [Abstract][Full Text] [Related]
16. VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.
Saponaro C; Malfettone A; Ranieri G; Danza K; Simone G; Paradiso A; Mangia A
PLoS One; 2013; 8(1):e53070. PubMed ID: 23326384
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
Arun B; Vogel KJ; Lopez A; Hernandez M; Atchley D; Broglio KR; Amos CI; Meric-Bernstam F; Kuerer H; Hortobagyi GN; Albarracin CT
Cancer Prev Res (Phila); 2009 Feb; 2(2):122-7. PubMed ID: 19174581
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.
Bukamal Z; AlRayes A
Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
[TBL] [Abstract][Full Text] [Related]
19. Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers.
Evans DG; Sithambaram S; van Veen EM; Burghel GJ; Schlecht H; Harkness EF; Byers H; Ellingford JM; Gandhi A; Howell SJ; Howell A; Forde C; Lalloo F; Newman WG; Smith MJ; Woodward ER
J Med Genet; 2023 Aug; 60(8):740-746. PubMed ID: 36442995
[TBL] [Abstract][Full Text] [Related]
20. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
